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This thesis is presented in the format of Journal of Animal Science, as outlined by 
the Oklahoma State University graduate college style manual.  The use of this format 




In the year 1993, the beef industry was struggling with the implications of the 
Jack-in-the-Box Escherichia coli O157: H7 tragedy and for the next 10 years, food 
scientists spent their time finding ways of reducing or eliminating E. coli O157: H7.  The 
disaster compelled many packers and further processors of beef to go out of business and 
the industry incurred more than $2.7 billion in loses. 
Today we hardly see any case of E. coli O157: H7 contamination or any recall 
related to it making headlines.  However, the lingering problem in the beef industry today 
is the rise of a new fatal and transmissible disease among cattle called Bovine 
Spongiform Encephalopathy (BSE).  The first confirmed case of BSE or mad cow disease 
in United States was reported in December of 2003 in a Washington state dairy cow.  
This discovery halted billions of dollars worth of beef exports and caused severe 
economic and political impacts across the nation.
 Bovine spongiform encephalopathy belongs to a group of diseases called prion 
diseases or transmissible spongiform encephalopathies (TSE) which are a set of fatal 
neurodegenerative disorders caused by modification of prion protein (PrP), a constituent 
of all the mammalian cells to an abnormal isoform designated PrPSc (Prusiner, 1991).  
The other prion diseases are scrapie in sheep and goats, kuru, Creutzfeldt-Jakob disease 
(CJD), Gerstmann-Straussler syndrome (GSS), and fatal familial insomnia (FFI) in 
human beings and encephalopathies in mink, cats, mule deer, and elk (Masters et al., 
1981; Medori et al., 1992; Gajdusek, 1997).  Prion diseases have generated a lot of 
interest in the scientific community not only because of their unique biochemical 
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characteristics but also because of their potential threat and impacts on the human health 
(Harris, 1999).  Over the past decade, more than 140 patients have died because of the 
new variant form of Creutzfeldt-Jakob disease (vCJD) caused by the consumption of beef 
contaminated with BSE material.  The contamination of the human food supply occurs 
when the BSE material from mechanically recovered meat (MRM) containing the central 
nervous system material of the cattle is mixed with processed meat.  Though most cases 
of BSE that occurred in European countries were indigenous in nature, these diseases can 
occur in any part of the world where BSE exists (Brown et al., 2003).  The US 
government, as elsewhere, has taken necessary steps not only to prevent the 
contamination of the human food supply with specified risk materials (SRM) coming 
from the by-products of a slaughtered cattle but also have acted to break the cycle by 
which the disease spreads from one animal to another(Brown et al., 2003).  However, the 
application of these regulations and strategies needs continuous monitoring to ensure 
compliance (Brown et al., 2003).
Complementary strategies involving better inactivation techniques and detection 
methods in the human food supply would therefore be an attractive way of BSE 
surveillance.  In order to achieve this objective, it is imperative to understand not only the 
biochemistry of abnormal prion protein but also the normal isoform of prions (PrPC).  A 
key obstacle to developing these strategies is the availability of PrPC in sufficient 
quantities in order to conduct studies to enhance our understanding its properties.  Even 
though the availability of PrPC in the brain is quiet high when compared to other tissues, 
its representation is less than 0.1% of the total proteins in the central nervous system 
(Riesner, 2003).  Purification of PrPC from a tissue source has often led only to 
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disappointment, as it is extremely difficult to obtain large amounts of the protein 
(Mehlhorn et al. 1996).  For example, from 100 hamster brains only a few micrograms of 
PrPC could be extracted using the optimal procedure (Riesner, 2003).  The availability of 
large quantities of purified recombinant PrPC should therefore facilitate the study of the 
structural properties of PrPC.  In the past, scientists have produced recombinant PrPC of 
various species in a variety of expression system including mammalian, baculovirus, 
vaccine virus, bacteria, and yeast.  However, considerable amount of problems were 
faced during the expression and purification of recombinant PrP because of low 
expression, insolubility and protein instability during the process (Baron et al., 1999). 
Syrian Hamster (SHa) PrP full-length mature protein 23-231 were highly expressed  
using a bacterial vector and the maximum expression was achieved for the region 90-231 
which corresponds to the protease resistant core PrP 27-30 (Mehlhorn et al. 1996).  Baron 
et al (1999) overexpressed   PrPC from sheep in large amounts in E. coli using amino 
terminal fusion with glutathione-S-transferase (GST) and carboxy-terminal fusion with 
hexahistidine sequence with varying affinity of each of the expressed protein on Western 
blots (Baron et al., 1999). 
Recombinant sheep prion protein (RecShPrPC) is also produced commercially by
firms like AJ Roboscreen GmbH, Leipzig, Germany who has  produced histidine-tagged 
full-length mature part of sheep PrP (25-234)  expressed in E. coli BL21, solubilized 
from inclusion bodies in 6 M guanidine-HCl, and purified by Ni(II)-nitriloacetate agarose 
chromatography.  However commercially available products like this costs more than 
$3,000.00 per milligram which would be very expensive for research needing large 
quantities of PrP.
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The objectives of this study was to overexpress the sheep prion protein as a fusion 
using the carboxy-terminal hexahistidine tag, solubilize it in  8M guanidinium chloride  
and purify it using a Ni-column affinity chromatography.  Also the expressed protein was 
detected using a Western blot assay.  Scrapie is the spongiform encephalopathy found in 
sheep and goats.  We decided to use normal sheep prion protein for our expression 
studies for two reasons: (1) Sheep PrP (ShPrPC) is one of the most studied and well
understood prions proteins, and (2) the ShPrPC sequence significantly differs from human 
PrP, implying that considerable barrier for the transmission of scrapie or ShPrPC to 
humans.  It is highly unlikely for the scrapie to be transmitted to human beings because 




2.1. Prions – An Overview
The early history of prion molecule goes back to the study of the physical and 
bio-chemical structure of the scrapie infectious agent.  Unlike a virus, prions demonstrate 
highly enigmatic properties like resistance to high temperatures and other physical and 
chemical treatments, absence of particles when seen through an electron microscope and 
no immune response during infection (Alper et al., 1966).  Alper et al (1966) concluded 
from their studies that scrapie agents have characteristics more similar to proteins than a 
virus as they were too small (50-150 kDa) to be a virus.  The mystery of scrapie agent 
was later resolved by Prusiner who not only did biochemical and physical studies but also 
performed a lot of enzymatic studies on the scrapie agent and  also coined the term 
“prion” (pronounced pree-on) derived from proteinaceous and infectious, as they were 
different from viruses, plasmids and viroids (Prusiner, 1982).  He noted two key results 
from his experiments: (i) the scrapie agent has no effect on procedures that modify or 
destroy nucleic acids, and (ii) the procedures that modify or destroy proteins inactivate 
scrapie agent (Prusiner, 1982).  Prions are mysterious infectious particles which cause a 
set of neurodegenerative diseases caused by a completely novel mechanism (Prusiner, 
1998).  Prion diseases in humans may occur as genetic, acquired or sporadic forms and in 
all situations, the cellular prion protein (PrPC) which is constituent of all mammalian cells 
is converted into an abnormal form designated PrPSc followed by accumulation of PrPSc
in neuronal and/or lymphoid tissues (Riesner et al., 1983). 
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Creutzfeldt-Jakob disease (CJD) is an example of prion disease in humans with 
rapidly progressing dementia eventually leading to the death of the victim in 3-4 months 
whereas BSE in cattle and scrapie in sheep and goats are ataxic illnesses (Collinge and 
Rossor, 1996; Prusiner, 1998). 
2.2. Terminology
Amyloid
The term Amyloid is used for deposition of pathologic protein filaments.  These 
filaments exhibit green-gold birefringence when stained with Congo red and seen under 
polarized light.  Amyloids formed in a prion disease are called cerebral amyloids 
(Prusiner et al., 1983). 
Amyloid Plaques
Amyloid plaques are formed when protein filaments aggregate in the extra 
cellular spaces of brain (Prusiner et al., 1987).
Chronic Wasting Disease
The transmissible neuro-degenerative disease found among mule deer and elk 
presumably caused by prions.  The hallmark of this disease is also the formation of 
amyloid plaque in the brains of the diseased animal (Williams et al., 1982).
Cosmid
A hybrid plasmid that contains cos sites at each end.  Cos sites are recognized 
during head filling of lambda phages.  Cosmids are useful for cloning large segments of 
foreign DNA (up to 50 kb).
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Creutzfeldt-Jacob Disease
Creutzfeldt-Jacob Disease (CJD) is a transmissible neuro-degenerative disease in 
humans caused by prions.  Patients with CJD exhibit a progressing dementia with 
myoclonus and a characteristic electroencecephalgram (ECG) showing pseudo periodic 
sharp complexes eventually leading to death of the patient in 3-4 months (Collinge and
Rossor, 1996).  CJD occurs at the rate of one per million population annually across the 
world and the onset of disease occurs at an average age of 65 years and is rarely seen 
below the age of 35 years (Collinge and Rossor, 1996).
Gene
Structurally, a basic unit of hereditary material; an ordered sequence of nucleotide 
bases that encodes a product (this product could be just RNA like rRNA or finally coding 
for a protein).  The gene includes, however, regions preceding and following the coding 
region (5' UTR and 3' UTR) as well as (in eukaryotes) intervening sequences (introns) 
between individual coding segments (exons) (Biochemistry, 2002).
Leader Sequence
It is the sequence at the 5' end of an mRNA that is not translated into protein.  It is 
also the length of untranslated mRNA from the 5' end to the initiation codon AUG.  It is 
the polynucleotide sequence between promoter and structural gene, necessary for correct 
transcription of DNA into mRNA (Collinge and Rossor, 1996). 
Meat and bone meal (MBM)
Meat and bone meal (MBM) is the dried and rendered product from mammal 
tissues which is considered a high source of protein.  It does not contain horn, hair, hide 
trimmings, manure, stomach contents, added blood meal or poultry by-product.  In the 
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year 1988 United Kingdom imposed a ban on the use of meat and bone meal in the 
animal feed (Taylor et al., 1994).
Open reading frame (ORF)
A section of a sequenced piece of DNA that begins with an initiation (methionine 
ATG) codon and ends with a nonsense codon.  ORFs all have the potential to encode a 
protein or polypeptide, however many may not actually do so (Collinge and Rossor, 
1996). 
Plasmid
Plasmid is a small infectious particle which is composed of circular double-
stranded DNA and without any protein in it.  They are usually found in bacteria and 
sometimes in eukaryotic organisms with an average size anywhere between 1 – over 400 
kilo base pairs (kbp) (Holmgren and Lefers, 2002). 
Prion protein
Prion proteins are the protease resistant glycoprotein core obtained while 
enriching fractions from Syrian hamster brain for scrapie infectivity and is designated as 
PrP 27-30 which has an apparent molecular weight of 27,000 to 30,000.  PrPC is derived 
from prion protein.  PrP 27-30 is obtained from digesting the PrP 33-35Sc with proteases 
which has an apparent molecular weight of 33,000 to 35,000 on an SDS-PAGE gel.  The 
superscript Sc is used to differentiate it from its cellular (C) isoform PrP 30-35C
(Prusiner, et al., 1987).
Prion protein Gene
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The prion protein gene has been identified in many organisms including humans 
(Chesebro et al., 1985).  The human prion gene is designated PRNP and is located on the 
short arm of chromosome 20 (Sparkes et al., 1986). 
Scrapie
Scrapie is the prototype for prion diseases.  It is a transmissible neuro-
degenerative disease in sheep and goats caused by prions characterized by prolonged 
incubation periods preceding the onset of critical illness.  Other neurological symptoms 
include ataxia, pruritis and incoordination (Prusiner, 1994).  Like other prion diseases, it 
is progressive and fatal in nature.
Specified Risk Materials
Specified Risk Materials (SRMs) are tissues in BSE-infected cattle, which have 
been shown to contain the infective agent and transmit the disease.  SRMs in all cattle are 
tonsils and distal ileum of the small intestine.  Brain, skull, eyes, trigeminal ganglia, 
spinal cord, dorsal root ganglia (DRG), vertebral column, excluding Vertebrae of the tail 
Transverse process of the thoracic and lumbar vertebrae are SRMs in cattle that are 30 
months and older (Turk et al., 1988).
Tranformation
It is the process of introduction of an exogenous DNA into a cell, causing it to 
acquire a new phenotype. 
Variant Creutzfeldt-Jacob Disease (vCJD)
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The year 1994 saw the emergence of a new form of CJD in United Kingdom 
which was distinctive from classical CJD; young age at onset, psychiatric and sensory 
symptoms and long disease course.  All the cases of this variant CJD (vCJD) is 
homologous at codon 129 for methionine (Will et al., 1996).  The prion found in BSE and 
in vCJD has the same physical and chemical characteristics indicating the fact that they 
have common sources.  Hence, it is believed that vCJD is caused by the consumption of 
infected beef products (Hill et al., 1997).
Vector
A vector is a DNA molecule known to replicate autonomously in a host cell, to 
which a segment of DNA may be spiced in order to bring about it replication; i.e., a 
plasmid or a temperate-phage DNA (temperate phage DNA is incorporated into host 
genome as prophage which replicates with the host bacterium, whereas virulent phage 
lyses the host cell).
Viroid
Viroids are small infectious pathogens which are entirely composed of low-
molecular weight RNA. Viroids use the enzymatic machinery of the host for 
reproduction.  Viroids have been found only in plants (Prusiner, 1994).
Virus
Viruses are a small infectious pathogen composed of one or more than one 
nucleic acids and covered with coat of protein.  Some viruses are also coated with lipid 
and carbohydrates.  Viruses direct the synthesis of their progeny by using its nucleic 
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acids and making use of the enzymatic machinery of the host (Prusiner and McKinley, 
1987).
2.3. The Prion Hypothesis
A large amount of research data supports the ‘Protein only’ hypothesis, even 
though the exact nature of the physical characteristics of prion is not known as first 
described by Griffith (1967) and later in a detailed manner by Prusiner (Prusiner, 1982). 
According to Prusiner, the transmissible agent does not have a nucleic acid and converts 
the rest of the normal protein into the abnormal protein PrPSc (Prusiner, 1982).  This 
proposal is supported by recent findings showing that mouse PrPc expressed in yeast and 
neuronal tumor cells can be changed into a form resembling very closely to the naturally 
occurring mouse prions (Sims, 2000).  It is not beyond doubt that these transgenetically  
produced prions would infect mice in the absence of a virus or virino.  If proved so, it 
would remove the doubt among the skeptics who still believe the virus or virino concept 
behind the TSEs (Riesner et al., 1983).  Now there are other reasons why scientists have 
abandoned the virus or virino hypothesis.  Firstly, the size of the prion protein is much 
smaller than any virus (Riesner et al., 1983).  Secondly; TSE scientists could not yet 
identify a scrapie specific nucleic acid (Riesner et al., 1983).  The presence of different 
strains of prions within the same species have raised questions about the protein-only 
hypothesis.  It is assumed that nucleic acids would explain the occurrence of different 
strains as it provides the probability of mutations.  However the different physiochemical 
properties of infectious protein (PrPSc) like glycosylation and proteolysis both 
endogenous and exogenous, explains the strain differences in scrapie (Collinge et al., 
1996).
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2.4. Prion Protein (PrP) genetics and expression 
2.4.1. Prion protein gene structure
The prnp gene, which codes for the prion protein is present in most mammals and 
is highly conserved across species (Van et al., 2003).  The entire open reading frame 
(ORF) of the PrP gene of all the mammals and bird species tested so far lies on a single 
exon (Prusiner, 1989).  In sheep, rat and cattle, there are three exons for the PrPC gene 
and the exon 3 has the ORF, which is analogous to exon 2 of the SHaPrP (Syrian 
Hamster) gene.  The exon 1 and exon 2 of the SHaPrP gene is separated by a 10-kb intron 
where exon 1 has the 5’ untranslated leader sequence and exon 2 has both 3’ untranslated 
leader sequence and the SHaPrP gene (Prusiner, 1989). 
The sequence comparison study of SHa- and MousePrP (MoPrP) genes reveal 
that the promoter regions of both species have multiple copies of G + C rich repeats and 
they also lack the TATA box (in eukaryotes TATA box helps the RNA polymerase to 
bind to the promoter sites and begins transcription).  These G + C repeats in these species 
may function as a binding site for the transcription factor Sp1 (Basler et al., 1986).  The 
mapping of HuPrP to the short arm of chromosome 20 is homologous to MoPrP mapped 
to chromosome 2 which supports the existence of PrP gene before speciation of mammals 
(Stahl et al., 1993).  The ORFs of PrP genes of many mammals and other class of 
organisms including humans have been sequenced and they all encode prion proteins of 
approximately 250 amino acids with N-terminal signal peptides (Kretzschmar et al., 
1986).  The N-terminal  portion of all the PrP ORFs also have a series of glycine rich 
regions.  The C-terminal region of all the PrP ORFs encode for a hydrophobic peptides 
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which later is presumable replaced with a GPI anchor and it also carries two consensus 
sites for glycosylation of asparagine and cysteines (Prusiner, 1989).
2.4.2. Prion protein expression
The mRNA of PrPC is expressed constitutively in the brain and many other cell 
types of all the adult mammals however, it is highly regulated during development 
(Basler et al., 1986).  Levels of PrP mRNA and choline acetyltransferase in septum 
increased during the development stage.  In situ hybridization studies shows that PrP is 
expressed in the highest levels in neuronal cells.  In some parts of the brain, PrP is 
expressed at an early stage (Basler et al., 1986).
Expression of PrPC was determined in the brain by immuno-histochemistry and 
by histo-blotting of both infected and uninfected brains.  Immunostaining of PrPC in SHa 
brain was very prominent in amygdala region of brain whereas immunostaining of PrPSc
was less intense in the same region.  Similar relationships between PrPC and PrPSc were 
observed in other parts of the brain like stratum radiatum and stratum oriens of CA1 
region of hippocampus. In contrast, PrPSc accumulated in the medial habenular nucleus, 
the medial septal nuclei, and the diagonal band of Broca; in contrast, these areas were
virtually devoid of PrPC.
Expression studies in transgenic (Tg) mice indicated that the normal PrP play a 
crucial role in the transmission and pathogenesis of prion diseases, however they also 
noted that PrPSc is an equally important part of the prion particle (Prusiner, 1991).  In 
other knock out (KO) studies of mice conducted by Prusiner et al, they observed that 
prnp gene deficient (prnp0/0) mice were resistant to prions.  Brain extracts from these 
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mice were extracted at different time points and were bio-assayed and found out that 
there is no infectivity in the brains of the prnp0/0 mice.
2.5. Chemical properties of PrP and recombinant PrP
The single exon on the gene prnp encodes for a 256 – 264 amino acids (AA) 
precursor of an approximately 28 kDa  product which is further processed when a signal 
peptide of 22- to 24-AA is cleaved from both C- and N- terminals leading to mature 
protein of 231 to 253 AA consisting of approximately 209-210 residues(Riesner, 2003).
 Prusiner et al. (1983) showed that after limited proteolysis of the abnormal 
isoform of PrP, the amino terminus is truncated to form PrP 27-30, which is composed of 
~142 amino acid residues.
During trafficking of the peptide out of the cell, the signal peptide 1-22 AA is 
cleaved and a glycosyl-phosphatidylinositol (GPI) is anchored at the site of the peptide 
232-253.  Prion protein is anchored by GPI on the cell surface (Turk et al., 1988). 
Asparagine residues at 181 and 197 carry highly branched glycosylation with sialic acid 
substitution.  On a western blotting assay followed by SDS-PAGE separation of the PrP, 
three forms of glycosylation can be seen based on glycolsylation-unglycosylated, with 
one glycosyl-, and with two glycosyl-groups. A disulphide bridge is formed between 
Cys179 and Cys214
The complete coding sequence of a sheep (Ovies aries) prnp gene is shown 
below in Fig A (Heaton,M.P., Leymaster,K.A., Clawson,M.L. and Laegreid,W.W., 
Animal Health Research Unit, U.S. Meat Animal Research Center, Box 166, State Spur 
18D, Clay Center, NE, personal communication).  The original translation product is a 
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256 amino acid peptide and the N-terminal signal peptide is 24 amino acids long.  The C-
terminal peptide 235-256 is replaced by a GPI anchor.  Therefore, PrP 25-234 is the 





 (NCBI ACCESSION DQ345757) (Heaton,M.P., Leymaster,K.A., Clawson,M.L. and 
Laegreid,W.W., Animal Health Research Unit, U.S. Meat Animal Research Center, Box 
166, State Spur 18D, Clay Center, NE, personal communication).
2.6. Prion Detection
2.6.1. Introduction
Prions are infectious proteins, which act by changing the structure of the normal 
prion protein (PrPC) into an abnormal protein (PrPSc) in the host (Sailer et al., 1994).  
Even though this hypothesis is widely received among the scientific community, no 
direct and unquestionable proof is available (Cheesbro, 2002). Prusiner separated a 
protease and a heat resistant protein from the brain of a hamster infected by scrapie in the 
year 1982, and he termed it as PrPSc, which closely resembled the infectious agent 
(Cheesbro, 2002).  Charles Weissmann at the Institute of Molecular Biology in Zurich
(Basler et al., 1986) and Bruce Chesebro et al (1985) independently identified the gene 
PmP that encodes PrPC.  The activity of the gene PmP is seen not only in brain but also in 





was removed from the mouse genome to examine the effect on the development of the 
mouse but to the surprise of the scientists, it did not prevent the normal development of 
the mouse, but it still exhibited complete immunity against scrapie (BuÈeler et al., 1992; 
BuÈeler et al., 1993; Sailer et al., 1994).
The nervous system is the only organ system, which can be attacked very severely 
by the TSE infection.  This also applies to other prion diseases such as Creutzfeldt-Jakob 
disease, Gerstmann-Sträussler-Scheinker Syndrome, Kuru and fatal familial Insomnia 
and to all known prion encephalopathies of animals (Aguzi and Heppner, 2000). 
However, it is evident that prions can attack organs other than the nervous system as seen 
in the spleen of scrapie-infected mice (Aguzi and Heppner, 2000).
2.6.2. The Prion Conversion Reaction:
Molecular studies reveal that both PrPC and PrPSc are glyco-proteins and they 
weigh approximately 35KDa.  PrPSc is an abnormal isoform of the normal protein, which 
is anchored to the cell membrane by a glycosylphosphatidylinositol (Stahl et al., 1993). 
Both the proteins are chemically same, but differ in the conformation.  Though the same 
gene codes both isoforms, they exhibit different physiochemical properties because of the 
different post-translational processes, which happens once PrPC reaches the extra cellular 
location (Baslet et al., 1986).  The accumulation of PrPSc in the brain is a typical 
characteristic of all the prion diseases.  The study of the 3D structure of PrPC has given 
several insights and speculations on the mechanism of the conversion of PrPC into PrPSc
in familial spongiform encephalopathies (Pan et al., 1993).  However, it has failed to give 
proper insight into the structure of the high-resolution PrPSc isoform.  This study of 3D 
structure as seen in the following figure revealed that PrPC has a high α-helix content of 
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42% and a very low β-sheet content of 3%, whereas PrPSc has 21% α- helix and 54%  β-
Used with permission of Fred. E. Cohen Laboratory, University of California, San Francisco 
sheet content (Pan et al.,1993).  In order to explain the conversion of a normal PrPc
protein to an abnormal PrPSc from a misfolded PrPc, two models have been hypothesized: 
(i) the template assistance model which is also known as the ‘refolding’ model and (ii) 
the nucleation-polymerization of ‘seeding’ model (Aguzi and Heppner, 2000).  The first 
model talks about the high activation energy barrier, which prevents the conversion of 
PrPC to PrPSc spontaneously at detectable rates.  When PrPSc is introduced exogenously, it 
converts the PrPC into PrPSc (Aguzi and Heppner, 2000).  This might involve a lot of 
unfolding and refolding which explains the high energy and might involve an enzyme or 
a chaperone.
In the second model, the two isoforms are in equilibrium strongly favoring the 
PrPC (Telling et al., 1995). When the PrPSc combines with a crystal like PrPSc aggregate, 
the complex is stabilized and hence more of this complex is formed.  The PrPSc aggregate 




2.6.3. Immunohistochemical Detection of Prions
Researchers in the University of California - San Francisco have developed a 
highly sensitive test to detect the presence of infectious prion proteins (Safar et al., 2002). 
This test makes use of the high affinity antibody, which precisely detects even the 
smallest amount of infectious protease resistant prion proteins present in the meat.  This 
method is known as Conformation-dependent Immunoassay (CDI).  For the production of 
this bioassay, a genetically engineered mouse for the over expression of bovine prion 
protein is injected with prions from an infected BSE (Bovine Spongiform 
Encephalopathy) cow.  This transgenic mouse with the capability to express the bovine 
prion protein is more sensitive to a prion attack from the infected cattle than a normal 
mouse.  Scientists claim that the assay produced in this kind of a genetically engineered 
mouse can detect 10,000 times more infectious proteins than a normal mouse in a 
standard assay (Safar et al., 2002).  The older immunological techniques detect only a 
portion of the PrPSc in cattle.
Immunohistochemistry has become a standard tool for researchers in diagnostic-
pathology.  The objective with regard to the prion detection is to prove the presence of 
infectious protein in the body of an animal because most of the time, it is very difficult to 
differentiate the infected part of the body from the healthy parts.  Researchers at 
Prusiner’s Lab at UCSA are very confident about the performance of the new assay they 
have developed (Safar et al., 2002).  According to Safar (2002), they can use the CDI 
technique in cattle, to reduce the incidence of exposure of humans to prions.
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2.6.4. Conformation-Dependent Immunoassay
About 20 years ago, researchers in Prusiner Lab developed the standard 
technique, which involved the enzyme protease being used to inactivate the normal 
prions, found in brain.  Study has revealed that this protein is used for the signal 
transduction inside the cell (Chesebro, 2002). Scientists highlight the remaining protease 
resistant PrPSc with fluorescently lit antibodies that reacts with these resistant proteins 
(Farquhar et al., 1989; Safar et al., 2002).  However, the problem with this technique is 
that, a large amount of the abnormal protein is protease sensitive and is undetected by the 
antibody.  Therefore, scientists are not able to get a good idea of the actual amount or 
exact number of infectious particles present (Safar et al., 2002). 
The new technique involves the use of a high-affinity antibody, which identifies 
the PrPSc by its structure thus helping the scientists to get the actual amount of these 
proteins.  This does not make use of the protease enzyme.  At the onset, an infectious 
tissue extract in its natural form is treated with the high-affinity antibodies and the 
reactivity is measured.  Then the infectious protein is treated with certain chemical so that 
they are unfolded and the region hidden earlier is exposed.  It is then treated with the 
antibodies and the reactivity is measured.  The degree of reactivity of antibody is much 
higher in denatured protein than the native one.  The ratio of native diseased prion protein 
to the denatured one gives the actual amount of PrPSc in the tissue (Farquhar et al., 1989).
2.6.5. Immuno-double staining
Scientists have identified two techniques to study and identify the nature of PrPSc
molecule.  In the first technique, two different antibodies are used to immunostain two 
serial tissue segments one on each side; one antibody identifying the cellular component 
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and other binding the PrPSc (Noorden, 1986).  Secondly, a similar immuno-double 
staining technique using two different antibodies on a single tissue can be used on a 
single tissue segment (Hancock, 1984).  A color-coding is required in this kind of a 
labeling technique to identify and differentiate the antigen of interest.  The shortcoming 
with the first technique is the risk of a similar kind of tissue structure or cell is not being 
present in the adjacent segments.  Another disadvantage of the immuno-double staining 
technique is the incidence of cross-reactions between two individual methods of detection 
(Noorden, 1986).
2.6.6. Western Blotting
Western Blotting is one of the most often used methods for an immunoblotting 
technique.  With this technique scientists can detect the protein of interests using specific 
antibodies with very high accuracy.  Proteins, which are separated based on the molecular 
weight, are transferred from a Sodium Dodecyl Suphate (SDS) polyacrylamide gel to a 
nitrocellulose membrane.  The protein of interest is thereafter detected using specific 
antibodies (Towbin et al., 1979).  The detection method is similar to the one used in 
immunohistochemistry: the protein is first bound to an antibody and after that a 
secondary antibody is incubated with the primary antibody-antigen complex (Thuring et 
al., 2002).  Conventional staining, chemiluminescence, autoradiography or flurography 
are used for observing the antigen-antibody complex depending on the method of 
labeling the secondary antibody (Towbin et al., 1979).  In prion related diseases, western 
blotting has been in use for detecting the protease resistant protein in brain tissues of 
cattle, sheep (Katz et al., 1992), mice , humans  and hamsters.  This technique is also 
used to test the presence of prions (PrPSc) in Lymphoid tissues.  Scientists have identified 
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the use of Western Blotting in detecting BSE and scrapie in sheep on a large scale.  Upon 
treatment with Western Blotting technique, the PrPSc separates into 3 layers which is 
manifested as three bands on the blot: nonglycosylated PrPSc, monoglycosylated PrPSc
and diglycosylated PrPSc (Collinge et al., 1996; Thuring et al., 2002).  Each of these 
fractions has different molecular weights.  Based on the ratio of their molecular mass or 
the Glycotype pattern, scientists are able to identify the different strains of scrapie 
(Thuring et al., 2002).
2.6.7. Immuno-PCR
Sano et al (1992) developed a highly sensitive technique for antigen detection 
called Immuno-PCR which makes use of the molecular recognition property of antibody 
with the DNA amplification capacity of PCR (polymerase chain reaction).  This 
technique could detect nucleic acids at femto grams levels of molecules using PCR 
(Niemeyer et al., 1997).  Immuno-PCR is similar to an enzyme-linked immunosorbent 
assay (ELISA) and western blotting assay however it is much more sensitive in detection 
than both. Unlike ELISA, immuno-PCR makes use of an antibody instead of an enzyme. 
A primary antibody binds to the specific antigen and a biotinylated secondary antibody 
made against the primary is incubated together.  The whole complex is then reacted with 
streptavidin or neutravidin that has a natural affinity towards biotin, which is further 
incubated with biotinylated DNA that undergoes amplification in a PCR reaction.  This 
method was improved by the use of real-time PCR that would eliminate all the post-PCR 
analysis.  Gofflot et al (2005) used this technique to detect PrPSc with 100% specificity 
with a detection level of at least 10-fold lower than the conventional techniques.  This 
method could possibly be used to detect the very small amount of PrPSc deposits in 
22
tissues and body fluids and hence be used for monitoring effective decontamination and 
sterilization methods.
2.6.8. Conclusion
Ever since Prusiner identified prions as the cause of many neurodegenerative 
human diseases, scientists around the world have been working on a technique, which 
would be highly sensitive towards these infectious proteins.  So far there are no efficient 
tests available to detect TSEs completely.  CDI technique discovered at Prusiner Lab 
would be a great tool towards the detection of all prion related and many other 
neurodegenarative diseases, which can be understood better.   
2.7. Degradation of Prions in Meat
Several incidents of prion infectivity among humans (Creutzfeldt–Jakob disease 
or CJD) were reported in Britain and France in late 80s soon following an epizootic 
outbreak of bovine spongiform encephalopathy among cattle, which suggested scientists 
a connection between the two diseases (Will et al., 1996; Bruce et al. 1997).  As 
mentioned earlier, these set of diseases are extremely fatal in both animals and humans 
and hence require very effective therapeutics (Stahl et al., 1993).  Scientists have 
discovered a number of chemicals, which have shown a minimal effect in the degradation 
of these infectious protein and especially in the propagation inside the tissue of an 
infected animal.  Some of them are anthracycline, sulfated polyanions, amphotericins, 
Congo red dye and antibiotics which exhibit a modest curative effect on TSEs but are 
unable to completely degrade the preexisting prions (Supattapone et al., 1999).
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2.7.1. Destruction of Prions 
The wide array of degradation and inactivation techniques that have proven 
effective for conventional microorganisms have failed to inactivate the agents that cause 
prion related diseases in animals and humans (Kimberlin et al., 1983; Brown et al., 1986; 
Taylor et al., 1997; Taylor, 1999b; Taylor, 2002).  Some inactivation techniques, which 
were thought to be very effective for the degradation of prions, are now found to be only 
partially effective.  Such methods involve the exposure of the infected tissues to 1M 
Sodium Hydroxide for one hour at 37
o
C and autoclaving at 134-138
o
C (Porous-load 
technique) or autoclaving at 132
o
C (gravity displacement method) (Taylor et al., 1999a).
The other recommendation of the use of chlorine (20,000 ppm) in combination with 
sodium hypochlorite proved to be effective in decimating the infectious agent, however it 
renders the meat product inedible (Kimberlin et al., 1983; Taylor et al., 1997).  A number 
of research data indicates that, the prions can be completely destroyed by using the above 
mentioned techniques simultaneously or in a series at an autoclaving temperature of  
121
o
C (Taylor, 1999b).  However, it has been found that the presence of high amount of 
lipid concentration in the infectious tissues may lower the efficacy of autoclaving of these 
agents due to the hydrophobic characteristic of PrPSc protein (Appel et al., 2001). 
2.7.2. Effect of Temperature and Pressure
Dr. Paul Brown and his co-researchers at the National Institute of Health, 
Bethesda, MD, (Brown et al., 2003) have succeeded in significant reduction of the 
infectivity of prions in processed meats using a combination of high pressure and 
temperature without affecting the texture and taste of the food.  They used the scrapie 
infected brain paste of 263K strain of hamster-adapted scrapie mixed with hotdogs, 
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which was subjected to high pressure and temperature.  Several short pulses of pressure 
ranging from 690 to 1200 MPa (up to approximately 100,000 psi) were applied to the 
hot-dog mix at a temperature of 121 to 137 0C.  Western Blot analysis of PrPSc showed 
that the high-pressure treatment achieved a reduction in the infectivity levels by 103 to 
106 mean lethal doses (LD50) per gram of the homogenate mix.  Maximum inactivation of 
4-6 log LD50 per gram was achieved at pressures of 1,000 MPa and 1,200 MPa. High 
pressure had been in used for more than 100 years for decimating the microbial 
population in food products, however this technique got more popularity with the advent 
of more sophisticated high pressure equipments (Brown et al., 2003).  Inactivation of the 
bacterial, viral, and fungal pathogens in the present day would have better results under 
hyperbaric and high temperature conditions with the exception of few like Listeria and λ
phage, which has inactivation temperatures near 00C.  Dr. Brown and his team are 
continuing their work on the degradation of prion using high pressure technology 
especially using different combinations of temperature, pressure and pulse rates and also 
in other TSE strains like natural and experimentally adapted BSE, nvCJD (Brown et al., 
2003).
2.7.3. Elimination of prions by branched polyamines and implications for 
therapeutics
Supattapone et al (1999) reported that the infectious prions (PrPSc) inside a 
scrapie-infected neuroblastoma (ScN2a) cell culture can be eliminated by the non-
cytotoxic concentrations of branched polyamines like polyamidoamide dendimers, 
polypropyleneimine, and polyethyleneimine (Supattapone et al., 1999).  The degradation 
of PrPSc in these cells depended on the concentration and time the cells were exposed to 
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the branched polyamines (Supattapone et al., 1999).  The exposure of ScN2a cells to 
these branched polymers for a period of one week reduced the PrPSc in these cells into 
undectable amounts.  This condition was maintained for a period of three weeks even 
after the withdrawal of the branched polymers from the culture (Supattapone et al., 1999).
 The structure-activity relationship (SAR) study indicates that the presence of the 
regularly placed primary amino structures on the polyamines is the key for the 
elimination of the infectious protein PrPSc from the cells.  A meticulous study of these 
structure-activity analyses suggests two to three mechanisms explaining the elimination 
process of PrPSc.  One of them suggests the binding of ligands present on PrPSc with the 
branched polyamines causing the opening up of negative moieties, which is followed by a 
conformational change (Supattapone et al., 1999).  This change is favored by the 
presence of an acidic environment.  The use of the heat resistant protease enzyme had a 
considerable effect on the scrapie-infected cells when the culture was first treated with 
branched polyamines at low pH (Supattapone et al., 1999).  Experiments suggest that 
acidic environment causes the PrPSc to unfold into monomers and as a result increases the 
concentration of α-helices. Another explanation is that the polyamines chelate the 
negatively charged moieties that are bound to PrPSc needed for protease resistance; 
however, they are released once the conformational change is complete under the acidic 
environment.  Clearly it indicates that more work is needed to understand the mechanism 
behind the action of polyamines on the PrPSc.
2.7.4. Enzymatic Degradation of Prion Protein
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Researchers at the North Carolina State University in association with the 
scientists from the Netherlands used the enzyme Keratinase derived from Bacillus 
liceniformis to successfully degrade the infectious isoform PrPSc of the normal cellular 
prion protein (Langeveld et al., 2003).  As mentioned earlier, this infectious protein is 
highly resistant to common treatments like boiling and activities of enzymes like 
proteinase K under normal conditions.  This method of degradation was aimed at 
decontamination of laboratory and medical equipment, which come in contact with the 
infectious materials.  The normal way of decontaminating the infected equipment in the 
lab is by boiling with 1% sodium dodecyl sulfate (SDS) with a reducing agent or treating 
it with chlorine, sodium hydroxide or formic acid (Taylor et al., 2000).  Since these 
methods have failed to yield the right results and also because of the harsh nature of these 
techniques towards the food product, scientists are looking for better alternatives.  As 
mentioned before, researchers at The National Institute of Health, MD, have used a 
combination of various treatments such as heat, temperature and pressure to mitigate the 
infectivity of prions significantly in processed foods (Brown et al., 2003).  Study on the 
use of enzymatic degradation of these infectious agents in conjunction with some of the 
conventional techniques like temperature and pressure has been shown to work better in 
the degradation process of prions, as it disrupts some of the hydrogen bonds, facilitating 
the solubilization and the digestion process by the enzymes (Laemmli, 1970).  This group 
of researchers also tested the effect of heating the infected homogenate in the presence of 
a detergent (N-Laurosylsacosine) on the prion degradation (Langeveld et al., 2003).  The 
test results and the western blot analysis indicated the reduction of the rogue PrP to 
immunochemically undetectable levels (Langeveld et al., 2003).  So these tests convinced 
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the scientists that it is possible to destroy completely PrPSc in BSE infected tissues and 
such techniques has the potential to bring about complete inactivation.
2.7.5. Conclusion
No effective treatments or techniques are available for inactivating the prions in 
the foodstuffs especially in processed meats.  However, the researchers at the North 
Carolina University have succeeded in inactivating prions in vitro or in test tubes to 
undetectable levels, which would be helpful in decontaminating medical and laboratory 
equipments (Langeveld et al., 2003).  Use of high pressure-temperature combination also 
has shown a reduction in prion in infected tissues.  Prusiner and his co-workers explained 
the action of branched polyamines on prions, which could be used in finding a 
therapeutic cure for prion related diseases.  The major concern from a food-processing 
standpoint would be to find a practical and commercial solution to eliminate prions from 
the food sources without effecting the texture and taste of the food. The objectives of this 
study were to develop a protocol for the over-expression of sheep prion protein in a 
bacterial cell line and its large-scale purification using a Ni-NTA column.  It would thus 
overcome the difficulties in extracting and purifying normal prion protein from tissue 
sources for the structural and biochemical studies.
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CHAPTER 3
PRODUCTION OF RECOMBINANT SHEEP PRION PROTEIN (RecShPrPc) 
AND ITS DETECTION USING WESTERN BLOTTING
AND IMMUNO-PCR
S. Thomas, S. C. Fernando, U. DeSilva, C. A. Mireles DeWitt
ABSTRACT
The objectives of this study were to over-express the sheep prion protein 
(RecShPrPC) using a bacterial vector fused with a C-terminal 6XHis-tagged fusion 
protein for large-scale purification using a Nickel-Nitrilotriacetate column 
chromatography.  The prion protein gene was PCR amplified using sheep genomic DNA 
and only the functional prion polypeptide (PrP 25-234) was sub-cloned into pET102/D-
TOPO plasmid after removing the sequences corresponding to the signal peptides from 
both N-terminal and C-terminal ends.  The integrity of the cloned PCR product as well as 
the His-tagged fusion protein and its orientation within the vector was determined by 
DNA sequencing and upon confirmation was induced with isopropyl-beta-D-
thiogalactopyranoside for protein expression. The expressed proteins were solubilized by 
addition of 8M guanidinium chloride in lysis buffer and purified using adsorption to a 
Nickel-Nitriloacetic++ metal affinity resin.  Purified proteins were detected at levels as 
low as 10µg using Western Blotting. Immuno – PCR is a recently described method for 
ultra-sensitive antigen assay, which was able to detect the RecShPrPC as low as 200 
femto-grams.  Production of RecShPrPC protein by this method could be used to study 
solubilization processes that fractionate muscle proteins.  Successful separation of 
myofibrillar and sarcoplasmic proteins from abnormal prion proteins may enhance the 
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safety of meat products that would eventually be rendered and used for non-mammalian 
animal feed or fertilizer. 
Key Words: Expression, Fusion Protein, His tag
INTRODUCTION
Scientists around the globe have shown intense interest in a group of transmissible 
neuro-degenerative diseases among which are spongiform diseases of cattle, scrapie of 
sheep, and Creutzfeld-Jacob disease of humans.  The agents responsible for transmitting 
these diseases are called prions, which are infectious proteins (Prusiner, 1994).  
According to Prusiner’s ‘protein-only’ hypothesis (Prusiner, 1982) the normal prion 
protein (PrPC) is converted to the abnormal isoform (PrPSc) by post-translational 
alterations to its secondary structure (Pan et al., 1993; Weissman, 1995).  Although
chemically identical to PrPC, sensitivity to proteases, different cellular distribution and 
altered solubilities all differentiate PrPSc from its parent isoform (Prusiner et al, 1983; 
Stahl et al 1993).  In order to understand the biochemistry and molecular mechanism of 
prions, it is key to study the structural properties of PrPC and PrPSc.  Attempts have been 
made in the past to extract and purify PrPC from tissues and bacterial expression systems, 
however very low expression and yield has hindered the process (Caughey et al, 1988; 
Scott et al, 1988).  Spectroscopic and NMR studies have been carried out successfully on 
hamster and mouse PrP fragments that were a part of the infective core of PrPSc
(Mehlhorn et al, 1996). 
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To overcome these issues, we expressed the full-length mature sheep PrP (25-
234) in a bacterial system fused with a  polyhistidine extension (His-PrP) at the C-
terminal end.  Sheep prion protein was selected because it was safer to deal with and is a 
much studied protein. The His-PrP was recovered from inclusion bodies with 
guanidinium chloride, purified by Nickel-Nitriloacetic++ affinity chromatography and 
confirmed using Western Blotting and Immuno-PCR.  Our future work includes the 




Polyvinyl-diflouride (PVDF) membrane, medium thick blotting paper, 2X 
Laemmli Sample buffer, and Proteinase K (200 µg/ml), was purchased from Sigma (St. 
Louis, MO).  Sucrose was obtained from United States Biomedical Corporation 
(Cleveland, OH) and agarose gel was obtained from MP Biomedical (Irvine, CA). 
Polypropylene plate were obtained from BD Biosciences (Franklin Lakes, NJ).  Plasmid 
extraction material was obtained from Qiagen (Valencia, CA).  The protein expression 
and purification material was bought from Invitrogen (Carlsbad, CA).  All chemicals 
used were of highest grade commercially available.
Cloning the Entire Open Reading Frame (ORF) of Sheep prnp Gene in Zero® Blunt 
Vector
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Polymerase Chain Reaction (PCR) Amplification. The ovine prion gene was 
amplified by the polymerase chain reaction using the following oligonucleotide primers: 
forward 5’-TGCTGCAGACTTTAAGTGATT-3’ and reverse 5’-
CCCCAACCTGGCAAAG-3’.  The PCR conditions were as follows; (i) Initial 
denaturation at 95 ºC for 1.5 minutes, (ii) denaturation at 94 ºC for 30 min, (iii) annealing 
at 58 ºC for 30 seconds and (iv) extension at 72 ºC for 30 seconds.   Steps (ii) to (iv) were 
repeated 34 times.   Since a native Taq polymerse enzyme was used for PCR, which does 
not have a proof-reading activity, it would add a 3’ A-overhangs on both strands.  To 
clean up the extra A’s, the PCR product was incubated with 10 µL of 10µg/µL 
exonuclease-1 (product number 70073Z, USB, OH, USA) at 37 ºC for 30 minutes.  The 
PCR product which was 893 bp was analyzed by 1.2% agarose gel electrophoresis for 
confirmation of the quality of PCR.  The gel was analyzed by an imaging system (GDS 
8000 system, UVP Bio-Imaging Systems, USA) 
Cloning of PCR Product into TOPO-Vector. The purified DNA from the gel 
(PCR product) was cloned into the TOPO vector by Chemical Transformation using 
Invitrogen’s Zero blunt PCR cloning kit (Carlsbad, CA) as described in manufacturer’s 
instructions.  Blue-white screening of the clones was done and the plasmid DNA was 
extracted from the positive clones as described in Sambrook and Russell (2001).
Extracted DNA was used as a template for PCR to confirm the insert.  The sequence of 
the isolated plasmid was confirmed by DNA sequence analysis with an Applied 
Biosystems Model ABI 3700 DNA analyzer.
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Cloning the Coding Sequence for the Mature PrPC Protein into pET102 Directional 
TOPO Vector with a His -Tag
Expression Construct. The expression vector pET 102/D-TOPO was obtained 
from Invitrogen Corporation, Carlsbad, CA (Cat # K102-01), which encodes a 13-kDa N-
terminal His-patch thioredoxin and has a C-terminal 6X-Histidine repeat which would 
later help in the purification process.  The 24 and 22 amino-acid signal peptide was 
removed from N-and C-terminal respectively and primers were developed to amplify the 
nucleotide sequence corresponding to the full-length mature PrPC (25-234).  PCR was 
performed using the following oligonucleotide primers: forward 5’-CAC CAA GAA 
GCG ACC AAA ACC TGG-3’ and reverse 5’- CAC ACT TGC CCC CCT TTG GTA-
3’.  The PCR was done using a high fidelity taq polymerase Platinum pfx DNA 
polymerase and the PCR conditions were: (i) Initial denaturation at 95 ºC for 2 minutes, 
(ii) denaturation at 95 ºC for 30 seconds, (iii) annealing at 58 ºC for 30 seconds, (iv) 
extension at 72 ºC for 45 seconds and steps (ii) to (iv) were repeated 34 times.
Ligation and Transformation of pET 102/D-TOPO into One Shot TOP10
Competent Cells.  The ligation and transformation was done using the materials 
obtained from Invitrogen’s Champion pET Directional TOPO Expression kit (Cat # 
K102-01) and by following the manufacturer’s instructions.  Positive clones containing
the complete plasmid were identified by plasmid isolation and PCR (using the above said 
conditions).  The sequence of the isolated PrPC-6XHis gene was confirmed by DNA 
sequence analysis (see above). 
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Overexpression of RecShPrPC-6His into BL21 Star (DE3) One Shot Cells
The transformation reaction of 10 ml was added to two 250 ml of Luria-Bertani 
medium containing the antibiotic ampicillin (50 µg/ml) and was incubated at 37 ºC with 
shaking at 250 rpms and was grown further until the OD600 reached between 0.5 – 0.8. 
These cultures were induced by the direct addition of 1mM IPTG (isopropyl-beta-D-
thiogalactopyranoside) for 4 hours.  The resulting cell pastes after centrifugation (3000g 
for 10 minutes at 4 ºC) were stored at -20 ºC.
Purification of the Fusion Protein RecShPrP Using Ni-NTA® Purification System
The purification was performed using the denaturing conditions as described in 
manufacturer’s instruction Invitrogens’ Champion TOPO® kit.  The Guanidinium Lysis 
Buffer, pH 7.8 (supplied with the champion kit) was equilibrated to 37 ºC and 0.2% 
sarkosyl salt was added to it.  The harvested cell paste stored at -20 ºC was thawed and 
resuspended in 8 ml of Guanidinium Lysis Buffer.  The cells were rocked slowly at room 
temperature for 10 minutes to ensure thorough lysis and disrupted by sonication (three 3-
second pulses at high intensity).  The cell lysate was divided into 2 ml centrifuge tubes 
and was centrifuged at maximum speed for 1 minute at 4 ºC.  The supernatant was 
aspirated into clean tubes.  The pellets were spun again at maximum speed and the 
supernatant was aspirated and saved (10 µL) for SDS-PAGE analysis and further 
purification with Ni-NTA column.  The aspirated supernatant was purified on a Ni-
Purification Column (supplied with the kit). 
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The protein was allowed to bind with Ni2+-nitrilotriacetate resin at room 
temperature for 30 minutes using gentle agitation to keep the resin suspended in the 
lysate solution.   The resin was settled using centrifugation at 800 x g and the supernatant 
was aspirated carefully.  The column was washed with 4 ml of Denaturing Binding 
Buffer by resuspending the resin and rocking for two minutes.  The resin was settled by 
centrifugation as before and the supernatant was aspirated and saved at 4 ºC for SDS-
PAGE analysis.  This step was repeated one more time. 
The column was washed with 4 ml of Denaturing Wash Buffer (pH 6.0) by 
resuspending the resin and rocking for two minutes.  The resin was settled by 
centrifugation as before and the supernatant was aspirated.  The supernatant was saved at 
4 ºC for SDS-PAGE analysis. 
The column was clamped in a vertical position and the cap on the lower end was 
snapped off.  The protein was eluted by the addition of 5 ml of Denaturing Elution 
Buffer.  Fractions of 1 ml were collected and the concentration was measured using a 
Nanodrop® ND-1000 Spectrophotometer (Delaware, USA) at the DNA-Protein Core 
Facility at Oklahoma State University, Stillwater (table). 
All the fractions were concentrated by speed vacuuming using a SC 210A Savant 
Speed Vac System, Ramsey, MN at the DNA-Protein Core Facility at Oklahoma State 
University, Stillwater and stored at -20 ºC. 
SDS and Western Blotting 
Protein samples were analyzed by SDS/PAGE according to Laemmli (1970).
Samples were denatured in 2x Laemmli Sample Buffer by boiling it  for 5 minutes at 98 
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ºC and were loaded on a 15 % pre-cast Tris-glycine gel (Life gel Cat # NG 11-420) to do 
the electrophoresis (P8DS™ Emperor Penguin Vertical Electrophoresis System, Owl 
Separation System, Portsmouth, NH).  Protein staining of the gel was done with 
Coomassie Brilliant Blue.  To perform western blotting, proteins from unstained SDS gel 
were transferred to a polyvinylidene diflouride (PVDF) membrane using HEP-1 
Panther™ Semi Dry Electroblotting System (Owl Separating Systems, Portsmouth, NH) 
at 2.5mA/cm2 of membrane surface area for 120 minutes.  After blocking with 3% gelatin 
in 20mM Tris, 500mM NaCl, pH 7.5 (TBS), the membrane was incubated with primary 
antibody (anti-prion mAb raised in mouse) at room temperature for one hour.  The 
membrane was washed thoroughly with 20mM Tris, 500mM NaCl, 0.05% Tween-20, pH 
7.5 (TTBS) to remove any unbound antibody and incubated with secondary antibody 
(Goat anti-mouse IgG HRP conjugate from Bio-Rad Laboratories).  After thorough 
washing with TTBS, the labeled fusion protein was detected using the HRP color 
development reagent as the substrate containing 4-chloro-1-naphthol and hydrogen 
peroxidase.
The primary antibody used in this study was a monoclonal mouse anti prion IgG1 
F89/169.1.5 (Sigma-Aldrich) that recognizes the amino-acid sequence IHFG of PrPC and 
PrPSc from a variety of species including sheep.
Immuno-PCR
Working on ice, antigen was diluted in PBS- containing polypropylene tubes to 
the indicated levels, then 50 ml of each dilution were added to separate wells, which were 
left to bind antigen for 16 h at 4
o
C.  Coating antigen dilutions ranged from 200ng to 
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200fg/ml, decreasing in serial 100-fold dilutions.  Unbound antigen was aspirated from 
the wells, which were washed four times with 150 µl PBS containing 0.05% Tween-20. 
Wells were blocked by incubation for 1 h at 37
 o
C with 150 ml of 10 mM Tris/HCl, pH 
7.6, containing 5% w/v non-fat milk powder, 0.9% w/v NaCl, 0.05 mM Thimerosal (5% 
milk powder buffer; MPB), then aspirated and washed as above.  Primary antibody (50 
µl) diluted as indicated in 0.5% MPB was added to wells and incubated for 2 h at 37 oC. 
After washing as above, wells were further incubated for 1 h at 37
 o
C with 50 ml of 
biotinylated donkey anti-mouse.immunoglobulin secondary antibody 2000-fold in 0.5% 
MPB, then washed and incubated for 1 h at 37
 o
C with 50 ng Streptavidin in 50 ml of 
0.5% MPB.  Following washing to remove unbound Streptavidin, wells were incubated 
with 854 fmol of biotinylated PCR target DNA in 50 ml of 0.5% MPB, for 1 h at 37
 o
C. 
Unbound target DNA was then rigorously removed by washing wells five times with 
PBSrTween, soaking wells for 3 min with wash buffer during each cycle, followed by 
two washes with ultrapure, 0.2 mm filtered water.  After addition of PCR reagents, well 
contents were subjected to 30 cycles of PCR amplification, using Bio-Rad real time 
thermocyler.  PCR was performed in 15 µl mix containing 7.5 µl Syber Green mix (A&B 
Warrington, UK), 0.3 µl each of forward and backward primer and 6.9 µL of autoclaved 
ddH2O. 
RESULTS AND DISCUSSION
The conundrum surrounding the structural transformation of the normal prion 
protein to the abnormal ones in the absence of any known chemical agent has intrigued 
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the scientific community for a long period (Pan et al., 1993; Stahl et al., 1993).  
According to previous research, the abnormal isoform of prion acts as a template in the 
formation of nascent PrPSc from normal isoforms.  However, more research needs to be 
done in order to understand their behavior in a multi-protein matrix and this can be 
achieved partly through the study of these two isoforms.   Prions, as discussed earlier in 
the article (Kay, 2005) are a significant food safety concern.  Research indicates that BSE 
in cattle is most likely caused by increased exposure of cattle to the scrapie agent, which 
survived in rendered sheep tissues, and ended up in meat and bonemeal (MBM; Taylor et 
al., 1997).  Therefore, it is imperative to find out newer methods of detection and 
separation of the abnormal isoform of prions from the normal ones in both animal and 
human food systems.  In order to learn more about these processes, it is important to 
study the two isoforms of prion at the molecular level.   Molecular models of purified 
cellular PrPC and PrPSc have been constructed using CD (secondary structure) and NMR 
(tertiary structure) techniques (Huang et al., 1994).  However, because of the difficulties 
associated with obtaining large amounts of PrPC from animal tissue, largely due to the 
highly unstable (Baron et al., 1999) and labile nature of PrPC, (K. O’Rourke, USDA, 
ARS, Washington State University, Pullman, WA, personal communication) expression 
techniques have been developed to study the protein. 
Initial attempts to express the whole protein using non-denaturing conditions 
resulted in low expression (Mehlhorn et al., 1996).  Researchers subsequently attempted 
to express only the putative part of the secondary structure of the PrPC residue (Gasset et 
al., 1992; Zhang et al., 1995; Mehlhorn et al., 1996).  These experiments were more 
successful in large-scale expression and detection.  Successful expression of the smaller 
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peptide residue has lead to further attempts to fully express the entire protein.   Several 
expression systems were examined for large-scale production of PrPC (Mehlhorn et al., 
1996).  Since initial attempts to express and purify parts of PrPC were conducted using 
non-denaturing purification conditions, subsequent attempts looked at both non-
denaturing and denaturing conditions.  However, even under strong denaturing 
conditions, the efficiency and yield of purification was very low (Pergami et al., 1996; 
Turk et al., 1988; Scott et al., 1988; Caughey et al., 1988).  The poor expression of the 
PrPC during large-scale protein expression was largely accounted to the N-terminal basic 
amino acid positions at 22-29 of Syrian hamster PrPC (Mehlhorn et al., 1996).
The normal prion-protein (PrPC) and PrPC-related proteins have been identified 
in many mammals, reptiles, birds and other organisms.  However, only one study has 
been reported so far on the expression of recombinant sheep PrPC (RecShPrPC) at the 
protein level (Baron et al., 1999).  In the current study, a Histidine tagged fusion system 
was used to overexpress the full-length (residues 25-234) of ShPrPC with Escherichia coli
following the removal of the N- and C-terminal signal peptides, and experiments were 
conducted to detect RecShPrPC in a muscle protein mixture using Western blot and 
Immuno-PCR.
We chose to express sheep prion protein (ShPrPC) for the large scale expression 
of the normal prion protein because ShPrPC is one of the most well defined and 
extensively studied prion proteins.  Also from a biosafety standpoint, ShPrPC was safer to 
work with because its sequence differs substantially from humans implying a significant 
barrier for the transmission of sheep prions to humans (Prusiner, 1989).  ShPrPC has 
shown to have an N-terminal signal peptide of 24 amino acids (Hope et al., 1986; Turk et 
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al., 1988).  As a result, the entire ORF encoded by the Ovis aries (sheep) prion gene 
(prnp) was cloned because it would facilitate further cloning of the nucleotide sequence 
(coding exactly the full length mature protein from lysine at the 25 amino acid (aa) 
position to serine at 234 aa position). 
Expression and Purification of the recombinant fusion protein His-PrPC-(25-234) 
into pET102 Directional TOPO® Vector 
The expression system pET102 Directional TOPO® Vector codes for a fusion 
protein of 366 amino acids, in which the sheep PrPC sequence 25-234 was linked into a 
42 amino acid C-terminal extension consisting a hexahistidine stretch which would 
facilitate the purification process by immobilized Ni-NTA chromatography column.  The 
DNA sequencing of extracted plasmid-PrPC gene verified its identity to sheep prion gene 
cDNA sequence by Heaton, M. P., Leymaster, K. A., Clawson, M. L. and Laegreid, W. 
W., (Animal Health Research Unit, U.S. Meat Animal Research Center, Box 166, State 
Spur 18D, Clay Center, NE, personal communication). 
Determination of the molecular weight (Mw) of the prion protein with the fusion 
protein (His tag) by Expasy software (Swiss Institute of Bioinformatics, Geneva, showed 
it to be 40 kDa (39,581.09 daltons).  The pI (Isoelectric point) of the protein was 
theoretically calculated as 7.77. According to Expasy, Mw of just the PrP (25-234) 
mature protein was calculated to be 22,815.77 daltons with a pI of 9.99.
In the past, research has been carried out to express the prion protein in part or as 
a full-length mature protein (amino acids 25- 234) in various bacterial systems.  
However, these experiments were not carried out under conditions identical to each other 
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(Mehlhorn et al., 1996).  The expression was particularly low in the case of expressing 
the full-length mature protein either alone or as a fusion protein (Mehlhorn et al., 1996). 
Histidine tagged full-length mature part of RecShPrPC (25-234) expressed in E.coli BL21 
was solubilzed and extracted from inclusion bodies using 6 M guanidinium chloride.  The 
cell extract was sonicated first and then loaded onto a Ni-NTA affinity column. His-PrP 
was eluted as a major fraction when the pH was changed from 7.8 to 4.0.  The 
concentration of the protein was measured by the Nanodrop® ND-1000 
Spectrophotometer (Delaware, USA) at the DNA-Protein Core Facility at Oklahoma 
State University, Stillwater and it was determined to be 0.96 mg/ml. Figure 1 (lane 3) and 
Figure 2 has the purified RecShPrPC where a protein band of molecular weight 39 kDa 
can be seen.  In lane 4 of Figure 1, the unpurified fraction is seen as a smear and the 
protein bands are not very clear.  The recovery of recombinant protein from the inclusion 
bodies was maximized by the use of 6M guanidinium chloride, a low pH to guarantee 
protein stability, and a hexahistidine tag to permit purification by immobilized Ni(II) 
affinity chromatography.  In our purified fraction, approximately 3% of the extracted 
protein was His-RecShPrPC.  Therefore, by keeping the protein constantly in an oxidized 
environment and maintaining the above said conditions, a yield of 28 mg of His-
RecShPrPC per liter of bacterial broth, which is slightly better than the yields recently 
reported for an amino-terminally polyhistidine-fused bovine prion protein (Negro et al., 
1997) and scrapie protein (Baron et al, 1999).  It might be possible to improve efficiency 
of the purification by recharging the Ni-NTA resin each time it is used.  His-Select 
Nickel Affinity gel from Sigma-Aldrich, St. Louis, MO was selected because it gave 
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better results when compared to the affinity gel from Invitrogen Corporation, Carlsbad, 
CA
SDS-PAGE and Western Blot 
The elution fraction obtained after purification of proteins induced from His-PrP 
transformed bacterial clones contained the detectable protein with a mobility of 39-kDa 
(expected size 39.5-kDa) as shown by the Coomassie blue staining of SDS-PAGE (Fig. 2, 
lane 2).  The 39-kDa protein was recognized after Western Blotting by a monoclonal 
antibody (mouse IgG F89 / 160.1.5) against the prion protein (Fig. 3).  Sequencing of the 
cloned insert showed the expected stop codon from the reverse primer (without stop 
codon) in frame with the prion sequence, which confirms the right fusion protein.  The 
expressed recombinant fusion protein included the 23-kDa recombinant PrP (25-234), 13-
kDa peptide on the N-terminal end of the plasmid, which corresponds to the His-patch 
thioredoxin, and a 3-kDa peptide on the C-terminal end containing the 42-amino acid V5 
epitope and a hexahistidine (6xHis) region.  The plasmid vector used for expression 
pET102/D-TOPO had a 126 amino acid sequence between the T7 promoter and PrP 
sequence, which might have reduced the efficiency of expression.
Immuno-PCR
Cervenakova and Brown (2004) reviewed several detection techniques of prion 
diseases and they commented immuno- PCR as a potential method for detecting PrPSc at 
very low concentrations.  This technology, described previously by Case et al (1999) 
binds an antibody detection step similar to an ELISA with nucleic acid amplification by a 
real-time PCR procedure.  Immuno-PCR results were analyzed by running the PCR 
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product on a 1.2% agarose gel electrophoresis and visualized by ethidium bromide 
staining and by observing the intensity and appearance of a band representing the right 
product size.  Amplification was the highest for the 2 ng (lane 1) of  RecShPrPC protein 
followed by a decrease in the intensity at 200 femto-gram (lane 5) of prion protein 
(Figure. 4).  Further enhancement of the assay specificity may be possible by the use of 
an automatic plate washer, which would give uniform and accurate reading of each wash 
process.
Our original plan was to extract prion protein directly from tissue in order to 
evaluate whether a post processing solubilization process on meat proteins destined for 
rendering or disposal could be used to extract the majority of the edible meat proteins 
(myofibrillar and sarcolasmic) away from prions in meat.  However, as we had trouble 
like the other researchers in purifying prion protein, we started looking for alternative 
sources of large amount of PrPC for biochemical studies.  As a result, a protocol was 
developed to produce full-length mature sheep prion protein 25-234 (ShPrP [25-234]), 
fused with polyhistidine tag that can be easily cleaved after the purification step.  The 
present expression system should help in producing large amount of normal prion protein 
thus overcoming the difficulties experienced in purifying sufficient amount the protein 
from meat solubilization studies.  Future objectives include the use of a mammalian cell 
line for cloning the whole sheep prnp ORF without removing the signal peptides so that 
we can manifest the post-translational modifications present in prions from non-microbial 
sources.  In addition, it is also suggested that the mammalian construct of RecShPrPC
subsequently can be utilized to conduct an in-vitro conversion of the PrPC to PrPSc by 
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cyclic amplification of protein misfolding, resulting in indefinite amplification of PrPSc
(Castilla et al., 2005).
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Figure 1: Purified and Unpurified RecShPrPC - Kaleidoscope ladder (Lane 1), Standard 
Biotinylated ladder (lane 2), purified PrP (10 µg) (lane 3) and unpurified PrP (lane 4).
Figure 2: SDS-PAGE analysis of the purified  RecShPrPC, Molecular Std (lane 1) and 
1µg RecShPrPC (lane 2)
Figure 3: Western Blot Analysis using the monoclonal antibody F89 / 160.1.5 following 
purification of RecShPrPC. 1 µg of total protein was loaded in the lane 1 and 15 µg of 
kaleidoscope protein standard was loaded in lane 2. In lane 1, ~ 40 KDa is due to the 
RecShPrPC.
Figure 4: RT-PCR products from an Immuno-PCR ran on a 1.2% agarose gel. Peptide 
was applied to wells in decreasing order of magnitude from 2 ng/ml to 200 fg/ml. 
Immuno-PCR products were analysed by 1.2% agarose gel electrophoresis and visualized 
by ethidium bromide staining.  Each lane has prion protein ranging from 2 ng/ml  to 200 
fg/ml. 2 ng/ml (lane 1), 200 pg/ml (lane 2), 20 pg/ml (lane 3), 2 pg/ml (lane 4), 200 fg/ml 
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Preparation of Muscle Protein and its Combination with Recombinant Prion 
Protein (RecPrP)
Experiment 1. Experiments 1 and 2 were performed in order to extract 
myofibrillar protein from meat and combine it with the extracted sheep RecPrPC. 
However due to technical errors, we ended up extracting more of sarcoplasmic and very 
less myofibrillar protein.
 Comminuted lean beef muscle was diluted (1:9) with cold (4
 o
C) ddH2O and 
homogenized at 15,000 rpm using a polytron (Kinematica GmbH, Lucerne, Switzerland) 
for 30 seconds (Dewitt et al., 2002).  Samples were then centrifuged at 10,000g for 10 
minutes at 4
 o
C.  The supernatant was collected and analyzed using a Nanodrop® ND-
1000 Spectrophotometer (Delaware, USA) located at the core facility of Oklahoma State 
University, Stillwater.  Purified recombinant sheep prion protein (RecShPrPC) was added 
to the supernatant to a final concentration of 1% and 10%.  SDS-PAGE electrophoresis 
was performed as described by Laemmli (1970) with following modifications (39).  
Equal amounts of 2X Laemmli sample buffer was combined with protein- RecShPrPC
mixture and was boiled for 5 minutes.  20, 15 10 and 2 µg of RecShPrPC protein-meat 
protein complex was loaded on a 15% pre-cast Tris-Glycine gel (Bio-Rad Laboratories, 
Hercules, CA, Cat # 1611103) and run for 2 hours at 120 volts.  Western Blot was 
performed following the protocol mentioned previously.
Experiment 2. Purified RecShPrPC was combined directly to the comminuted 




(1:9) and homogenized at 15,000 rpm using a polytron for 30 seconds.  The sample was
centrifuged at 3000g at 4
 o
C for 10 minutes.  The supernatant was collected and stored at 
4
 o
C for doing SDS-PAGE. 
SDS-PAGE electrophoresis was performed as described by Laemmli (1970) with 
following modifications.  To prevent the proteins from precipitation at low pH, samples 
were diluted 1:4 with 5% SDS and 200 µL of the SDS-diluted sample (30 and 20 µg of 
RecShPrPC) was added to 50 µL of 1X Laemmli sample buffer and boiled as previously 
stated before loading.
RESULTS AND DISCUSSION
The concentration of extracted sarcoplasmic protein at OD280 was measured to be 
15 µg/µL.  In experiment 1, the mixture of recombinant fusion prion protein and muscle 
protein contained two detectable proteins with mobilities of 39 and 43-kDa, as shown by 
the Commassie blue staining of SDS-PAGE (data not shown).  However, western blot 
using antibodies against the prion protein did not give any signal (data not shown).  The 
most likely explanation for the negative results might be that both RecShPrPC and the 
sarcoplasmic protein got degraded in the presence of naturally occurring proteases.  A 
second possible explanation for a negative Western Blot result might be inefficient 
transfer of protein from the gel to the PVDF membrane.  Another possibility is that our 
detection system, which was a colorimetric assay, was less sensitive towards the color 
reaction when compared to other detection assays like chemiluminiscence assay.
The results for Experiment 2 also yielded negative and did not give any signal on 
the western blot analysis. 
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APPENDIX 2
Preparation of 1.2% agarose gel
1. Weigh 1.2 g of agarose (Cat # Sigma St. Louis MO) and add it to 100 mL TBE 
buffer in an Erlenmeyer flask.
2. Heat it in a microwave (approximately for 2 minutes) so that the agarose melts and 
being careful, that it does not boil and spill all over.
3. Working under the hood, add 7 µL of ethidium bromide (Cat # 7627, Sigma St. 
Louis MO) to the melted agarose while it is still hot and mix it by gently swirling it 
under the hood. (Note: Ethidium bromide is a carcinogen)
4. Make the gel cast (Cat # Bio-Rad) ready by taping both its ends to contain the 
melted agarose and then pour the agarose into it.   Place the comb and let it set.
10X TBE Buffer
Tris Base (Cat # T4661 Sigma St. Louis MO): 108g
Boric acid: 55g 
EDTA (Cat # E7889 Sigma St. Louis MO): 9.3g
ddH2O to: 1L
Total Volume: 1L 
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APPENDIX 3
Extraction of Genomic DNA from sheep tissue
1. Weigh out approximately 1 gram of sheep tissue (in our case we used obex region 
sheep brain, however for DNA extraction, any tissue like blood can be used) in a 50 
mL centrifuge tube and homogenize it with in 3mL of ice-cold lysis buffer (10 mM 
Tris-Cl, pH 8.0, 0.1 M EDTA (pH 8.0), 0.5% (w/v) SDS, 20 µg/ml DNase-free 
pancreatic RNase ) using a tissue homogenizer (Tissumizer, Tekmar Model Number 
SDT 1810 OH,USA).
2. To the cell lysate, add 50µL of proteinase K (200 µg/ml) (Cat # 82452 Sigma St. 
Louis MO) which would digest any protein and thus would increase the yield of 
genomic DNA.
3. Incubate the digest at 60ºC in a water bath or an incubator for 3 hours and transfer 
the lysate to a new 50 mL centrifuge tube.
4. Extract DNA  with 5 mL of phenol: chloroform: isoamyl alcohol (25:24:1) by 
spinning the tubes at 14000 rpm (Beckman J2 HS, USA) for 5 minutes at 4 ºC and 
transfer the supernatant to a new centrifuge tube.
5. Precipitated the DNA in the aqueous phase with 1 volume of 100% ethanol and 
1mL 10M ammonium acetate.
6. Determine the concentration of extracted genomic DNA using a Nanodrop® ND-
1000 Spectrophotometer (Delaware, USA). The concentration of DNA measured in 
this project was 1.178 mg/µL.
7. Dilute the DNA to final working concentration of 100 ng/mL and store at  -20 ºC. 
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8. Add 6 µL of DNA (100 ng/mL) to 2 µL of 6X sample buffer and load it on a 1.2% 
agarose gel.  Separate the DNA in an electric field by running at a voltage of 140 V 
for 20 minutes.  This step is done in order to see if the extracted DNA is denatured 
or not.
9. Analyze the gel using an imaging system (GDS 8000 system, UVP Bio-Imaging 
Systems, USA) to check the quality of obtained DNA.
6X Sample Buffer
Bromophenol blue: 2.5 ml
Xylene cyanol: 2.5 ml
Sucrose: 4.0 ml
ddH2O to 10 ml




1. This protocol is for developing primers for the nucleotide sequence encompassing 
the complete coding sequence the prion gene that is approximately 771 bases. 
2. Copy the complete coding sequence of the prion gene in the FASTA format from 
the NCBI site (http://www.ncbi.nlm.nih.gov) to the Sequence Input Box on the 
Primer3 site (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
3. Using the Primer3 website, pick a primer set (left and right) and optimize the 
various parameters (length of the primers, self-complementarity of the sequence, 
GC content, Tm difference etc) for an efficient primer giving minimal misbinding. 
4. Analyze the designed primers using IDT’s Oligo Analyzer 3.0 
(http://207.32.43.70/biotools/oligocalc/oligocalc.asp) for various parameters to 
ensure maximum efficiency.
5. Once the primer is developed, get it ordered from Integrated DNA Technologies Inc
(or any other vendor).
6. Working on ice, touch spin the obtained primers briefly on a table top centrifuge 
(5415 C Eppendorf, Westbury, NY) to collect all the primer, which is in the powder 
form to the center of the vial before diluting.  Dilute the primers to make 200 µM of 
stock solution by using the following equation.  The molecular weight of the 
forward primer used in this part of the current project was 6451.2 mg
Volume of ddH2O needed in µLs = 
The amount of ddH2O added to forward primer =  186 µL. 
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7. Similarly calculate the amount of ddH2O needed for the reverse primer.  The final 
working concentrations required for both primers are 25 µM which can be achieved 
by doing the following calculation.
V1  C1 = V2  C2, where 
V1 = Volume of the first solution
C1 = Concentration of the first solution
V2 = Volume of the second solution
C2 = Concentration of the second solution
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APPENDIX 5
Polymerase Chain Reaction (PCR)
1. Make the following recipe for the PCR mix:
DD H2O: 14.5 µL
PCR buffer (10X) 
(Cat # E08663, Applied Biosystems, Foster City, CA): 2 µL
MgCl2 (25mM)
(Cat # E08688, Applied Biosystems, Foster City, CA): 1.2 µL
Forward and Reverse primers (20mM): 0.4 µL
dNTPs (Cat # 170-8874, Bio-Rad Laboratories, Hercules, CA): 0.4 µL
Taq polymerase: 0.25 µL
Genomic DNA (100ng): 1.0 µL
----------------------------------------------------------------------------------------------
Total 20.0 µL
2. Touch spin the PCR mix on a table top centrifuge (5415 C Eppendorf, Westbury, 
NY) and put it on a thermocycler (DNA Engine DYAD®, Bio-Rad Laboratories Inc, 
South San Francisco, CA) with the following PCR conditions:
(i) Initial denaturation at 95 ºC for 3 minutes, 
(ii) Denaturation at 94 ºC for 30 seconds,
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(iii) Annealing at a 58 ºC for 30 seconds (This can be achieved by doing a 
gradient first). 
(iv) Extension at 72 ºC for 2 minutes and repeat steps (ii) to (iv) 34 times.
3. After the completion of PCR, add 2 µL of 6X sample buffer to the PCR product and 
run it on a 1.2% agarose gel (with ethidium bromide) to see the PCR results.
4 Visualize the gel using an imaging system (GDS 8000 system, UVP Bio-Imaging 




Agarose gel (1.2%) analysis of PCR product amplified using the extracted genomic DNA 
as the template for PCR. 1kb standard marker (lane 1) and 893 bp PCR product amplified 









Agarose gel analysis of the PCR amplified product of 893 bases using the DNA from cell 
burst as the template for PCR.  Upon screening for clones which has taken the insert 
using PCR, three positives A5, E5 and C3 were detected which had the DNA band of the 
right size of 893 base pairs.
 A5    E5
C 3
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APPENDIX 8
PCR product with and without stop codon - 1kb standard marker (lane 1), PCR products 
amplified off the ORF of PrP with stop codon (lane 2) and without stop codon (lane 3). 
Note that both the products have the same size of 633 bp, which encodes the 210 amino 
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H12
APPENDIX 9
Agarose gel analysis of PCR product, which is the coding DNA sequence corresponding 
to the mature prion protein PrP-(25-234), Screening of Positives Clones With and 
Without Stop Codons - Out of more than 50 clones screened, only 4 clones were positive 
for the right insert of 633 base pairs.  Figure A. H12 and A11 were the positive clones 
with the stop codons, which we did not use it for expression.  Figure B. E8 and H12 were 
positive with out a stop codon. E8 was used for the expression purposes.
     H12  A11
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DNA sequence analysis of the complete ORF of the prion protein gene (prnp) of clone C3
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DNA sequence analysis of the complete ORF of the prion protein gene (prnp) of clone C3
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DNA sequence analysis of the complete ORF of the prion protein gene (prnp) of clone A5
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DNA sequence analysis of the complete ORF of the prion protein gene (prnp) of clone A5
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DNA sequence analysis of the complete ORF of the prion protein gene (prnp) of clone E5DNA sequence analysis of the co plete RF of the prion protein gene (prnp) of clone E5
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